Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies. Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.
Stock data | 2024 | Change |
---|---|---|
Shares Outstanding | 3.21M | N/A |
Employees | 96.00 | N/A |